Switching to subtenon triamcinolone acetonide does not jeopardize the functional and anatomic outcomes of dexamethasone implant treated eyes with diabetic macular edema-Reference-Cited by-同舟云学术

Switching to subtenon triamcinolone acetonide does not jeopardize the functional and anatomic outcomes of dexamethasone implant treated eyes with diabetic macular edema

Published:2024-04-26 Issue: Volume: Page:
ISSN:0721-832X
Container-title:Graefe's Archive for Clinical and Experimental Ophthalmology
language:en
Short-container-title:Graefes Arch Clin Exp Ophthalmol

Author:

Borella Ysé,Bertaud Samuel,Tadayoni Ramin,Bodaghi Bahram,Dupas Bénédicte,Touhami Sara^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00417-024-06492-z.pdf

Reference43 articles.

1. Antcliff RJ, Marshall J (1999) The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 14:223–232. https://doi.org/10.3109/08820539909069541

2. Bressler NM, Beaulieu WT, Maguire MG et al (2018) Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes with Diabetic Macular Edema in Protocol T. Am J Ophthalmol 195:93–100. https://doi.org/10.1016/j.ajo.2018.07.030

3. Munk MR, Somfai GM, de Smet MD et al (2022) The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers. Int J Mol Sci 23:7585. https://doi.org/10.3390/ijms23147585

4. Vujosevic S, Toma C, Villani E et al (2020) Diabetic macular edema with neuroretinal detachment: OCT and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids. Acta Diabetol 57:287–296. https://doi.org/10.1007/s00592-019-01424-4

5. Zhang J, Zhang J, Zhang C et al (2022) Diabetic Macular Edema: Current Understanding. Mol Mech Therapeutic Implications Cells 11:3362. https://doi.org/10.3390/cells11213362